Expert faculty review and share their insights and perspectives on key studies on the management of acute and chronic leukemias presented at the virtual Hematology 2020 annual meeting.
In this commentary, 2 experts discuss their top presentation choices from ASH 2020 in acute and chronic leukemias with the most potential to impact practice.
Experts discuss results and implications from 3 of the key studies in acute myeloid leukemia and chronic myeloid leukemia from the virtual Hematology 2020 meeting, including magrolimab in AML, the STAMP inhibitor asciminib in CML (the ASCEMBL trial), and optimal dosing for ponatinib in CML (the OPTIC trial).
Review expert perspectives on the most clinically relevant data on indolent and aggressive lymphomas presented at the 2020 ASH annual meeting.
In this commentary, Jeremy S. Abramson, MD, MMSc, discusses the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Review expert perspectives on the most clinically relevant data on myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2020 ASH annual meeting.
In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in MDS and MPNs with the most potential to impact clinical practice.
In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.
Expert faculty review and share their insights and perspectives on key findings in multiple myeloma from ASH 2020.
In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in myeloma with the most potential to impact clinical practice.
Two experts discuss results from key studies in multiple myeloma from the virtual Hematology 2020 meeting, including updated data on treatment options for newly diagnosed disease and an analysis of available agents for relapsed/refractory myeloma.
Review expert perspectives and insights on the most clinically relevant data on ITP, hemophilia, β-thalassemia, sickle cell disease, and GVHD presented at the Hematology 2020 annual meeting.
In this commentary, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, share their top choices of new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.
In this podcast episode, listen to Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, discuss their takeaways on new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.
Review experts' perspectives on the most clinically relevant data on malignant and nonmalignant hematology results to be presented at the ASH 2020 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.